TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Efficacy of n-3 PUFA in reducing psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence ratio for acute MI
Endpoint domain: Mortality/survival
Primary endpoint: Nociception flexion reflex (NFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary dilatation reflex (PDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's development quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental stress, depression and coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental problem solving skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in the total number of cataplexy attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life (baseline)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (followup)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of Jackhammer esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spontaneous premature birth
Endpoint domain: Mortality/survival
Primary endpoint: Minutes of moderate-to-vigorous physical activity per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of HBV reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Scores Following Caesarean Section at 8 Hours Post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Scores Following Caesarean Section at 24 Hours Post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum insulin degludec concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the plasma liraglutide concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of injuries diagnosed by WBCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful catheter insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent change in LDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of responders to the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRT thresholds changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESRT thresholds changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of chronic hepatitis B patients with chronic hepatitis D infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality of Life (QOL) experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Development of PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of adverse event of special interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: TV negative by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pupillary Reflex Dilation (PRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Binding Potential of Dopamine Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mean 24 hour Systolic Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in ALS Functional Rating Scale-revised (ALSFRSr) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event Reporting Rate
Endpoint domain: Adverse events/effects
Primary endpoint: time-to-ITTVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rank-transformed Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late loss (LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TLF rate
Endpoint domain: Adverse events/effects
Primary endpoint: maximal detrusor storage pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of anaerobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence Rate of Target Aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Range of motion of lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2-Year Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Generalized Anxiety Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicidal thoughts and behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Family planning utilization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change From Baseline in the Standard Deviation of the Lateral Position (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain score comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until PACU Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PASI Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prolapse Efficacy - POP-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Incontinence Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental score examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CBT Treatment Fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects meeting escape criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss (BMI, Intra-abdominal fat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being (physical, psychological, cognitive-affective, social-spiritual, and overall)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of women responding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early neurological deterioration within 3 weeks after stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 90-days prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve from the time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response of Actinic Keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cough Reflex Sensitivity to Capsaicin Measured by Maximal Cough Response (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cough Reflex Sensitivity to Capsaicin Measured by the Tussive Concentration Required to Achieve 50% of Emax (ED50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plaque burden in carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity/specificity for water versus air for distension of colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: athletic adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colorectal Cancer Recurrence or Metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Overall Response Rate (ORR) in Chronic Lymphocytic Leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate (ORR) in Non-Hodgkin Lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence & severity of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treated-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Fetal Heart Beats at 12 Weeks Gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Systemic VEGF-A protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Evaluation by Self-administered memory screening test with automated reporting (SAMSTAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Evaluation by Rey Auditory Verbal Learning Test (RAVLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6-month Reocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lesion-level positive and negative percent agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcriptomic profile of immune response genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of developing complications of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Severe Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Anti-velaglucerase Alfa Antibody
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infusion-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium assessment using CAM-ICU and 3-D CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of adverse pregnancy outcome
Endpoint domain: Adverse events/effects
Primary endpoint: composite neonatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of adverse reactions/events
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment in a Clinical Trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pro-saccades test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognition (PHES)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of Life (SIP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BBPS scores of the entire colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oxygen desaturation index 4% (ODI4%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen cumulative time below 88% (OCT88%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinic attendance for pills pick up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effective power of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change from baseline in 12 lead electrocardiogram parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of Dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MADRS Improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in MAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait performance adaptations to training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the composition of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inhibition of Intragastric Acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of Erythema migrans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraoperative glycemic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 8-hydroxy-deoxyguanosine (8-OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulvar pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response at 12 Weeks After HCV Treatment Discontinuation (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography features of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnetoencephalography features of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electromyographic activity of the gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Hair Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deposition of inhaled aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and expected toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients receiving surgery
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe infectious morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Consumption of propofol during anesthesia maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fidelity to the Program Model
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CINV at the delayed phase during cycle 2
Endpoint domain: Adverse events/effects
Primary endpoint: Cystoid Macular Edema resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percent Complete Spontaneous Bowel Movement Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: successful re-use of isoniazid for TB treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Methamphetamine Selective Severity Assessment (MSSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine Withdrawal Assessment (MAWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac alterations during reperfusion phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxicity of Peginterferon Alfa-2b and Sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Access to, and Received the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of life related to Radiation Induced Nausea and Vomiting
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: poor outcome (mRS 4-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction and usefulness of education tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TME quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: circumferential resection margin (CRM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacists' dispensing of MAT medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacists' monitoring of MAT care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptability of pharmacy-provided MAT care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bacterial contamination of nasal saline irrigation bottle following normal saline solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bacterial contamination of nasal saline irrigation bottle following ChitoRhino irrigation solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-monitoring of diabetes management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrogen Receptor (ER) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite safety outcome of MRgFUS thalamotomy
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamics of retinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Drug Concentration Observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of a major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of obstructive sleep apnea syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sirolimus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Social Anhedonia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Anhedonia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prescription of evidenced-based preventative therapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of pulmonary vascular resistance (PVR) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of failed LMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: proportion of patients without AML relapse
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of Valproic Acid and 5-Azacytidine in MDS treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive incremental area under blood glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver Triglyceride Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with atrial function at echo-doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients on anticoagulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation in non-pharmacological options
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: latency of motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Distant Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of topical sirolimus in cutaneous microcystic lymphatic malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal function outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Subjects Who Completed CRC Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Participants Who Were Alive at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Ongoing pregnancy rate at 12 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Vitamin D 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes